381 completed, 157 unknown, 45 terminated, 32 withdrawn. 653 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 653 | Completed 381, Unknown 157, Terminated 45, Withdrawn 32, Recruiting 14, Not yet recruiting 12, Active not recruiting 10, Enrolling by invitation 2 |
Follow Hepatitis, Viral, Human: new trials by email Literature Review of Hepatitis, Viral, Human trials Research Report on Hepatitis, Viral, Human
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health. Gardasil 9 vaccine, Hepatitis B Virus Vaccine(HBV), Cognitive Behavioral Therapy - Hepatitis B, Human Papilloma Virus | Phase 4 | Not yet recruiting | Eunice Dube | 2140 | 2027-01-30 | 2026-07-30 |
| Combating Related Epidemics in HCV Cepheid GeneXpert HCV Test, Abbott Determine HIV - 1/2 Ag/Ab, Abbott Determine HbsAg 2 - HIV - Human Immunodeficiency Virus, Hepatitis B Virus (HBV) | Phase 4 | Not yet recruiting | Duke University | 1280 | 2027-01-20 | 2026-10-15 |
| AI-Powered Hepatitis C Single-Encounter Test-and-Treat Epclusa (sofosbuvir and velpatasvir) - HEPATITIS C (HCV) | Phase 4 | Not yet recruiting | Patrick Grace | 35 | 2026-12-01 | 2026-08-28 |
| Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Tolerant Chronic Hepatitis B Entecavir, Entecavir + Pegylated interferon α-2b - Hepatitis B Virus Infection, Children | Phase 4 | Not yet recruiting | Qing-Lei Zeng | 80 | 2026-01-11 | 2026-01-16 |
| Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Active Chronic Hepatitis B Entecavir, Entecavir + Pegylated interferon α-2b - Hepatitis B Virus Infection, Children | Phase 4 | Not yet recruiting | Qing-Lei Zeng | 60 | 2026-01-11 | 2026-01-16 |
| Strengthening Hepatitis B Screening, Linkage to Care and Long-Term Monitoring in Phichit Province, Thailand: A Birth Bohort Approach Tenofovir Alafenamide (TAF), Community-Based Support, Simplified WHO 2024 Criteria - Chronic Hepatitis B, Hepatitis B Virus Infection | Phase 4 | Not yet recruiting | The Task Force for Global Health | 6000 | 2026-01-01 | 2025-12-02 |
| Prospective Cohort Study on PEG-IFN-α-2b in Improving Clinical Cure Rate of Pediatric Patients With Chronic Hepatitis B Peginterferon alfa-2b Injection - HBV, Chronic Hepatitis B Virus | Phase 4 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 113 | 2026-01-01 | 2025-11-17 |
| Comparison of Viral Suppression With 0.5 mg and 1.0 mg Daily Doses of Entecavir in Decompensated HBV Cirrhosis of Liver Entecavir - Hepatitis B | Phase 4 | Recruiting | Bangladesh Medical University | 48 | 2026-01-01 | 2026-09-11 |
| Combined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors Entecavir, HBIG, EVLP UV Light Treatment - Hepatitis B Virus (HBV), Lung Transplant Recipient | Phase 4 | Recruiting | University Health Network, Toronto | 20 | 2025-09-24 | 2025-11-17 |
| Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard Strategy ACCESS+ strategy Epclusa 400/100 Oral Tablet, ACCESS+ Strategy Vosevi 400/100/100 Oral Tablet, Standard Strategy Vosevi 400/100/100 Oral Tablet - Hepatitis C Virus Infection | Phase 4 | Not yet recruiting | ANRS, Emerging Infectious Diseases | 576 | 2025-09-01 | 2025-08-01 |
| Clinical Efficacy of Pegylated Interferon Alpha-2b Combined With Nucleos(t)Ide Analogues in the Treatment of Chronic Hepatitis B Patients Peg-IFN α-2b combined with NAs - Metabolic Dysfunction-Associated Steatotic Liver Disease, Chronic Hepatitis B | Phase 4 | Not yet recruiting | Shenzhen Third People's Hospital | 830 | 2025-08-15 | 2025-07-17 |
| Implementing Low-Barrier HCV Treatment in a Jail Setting Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Community Health Worker - HEPATITIS C (HCV), Incarceration | Phase 4 | Recruiting | Lifespan | 40 | 2025-06-11 | 2026-02-27 |
| Pegylated Interferon Alfa-2b in Reducing Relapse Rates After Nucleos(t)ide Analogue Withdrawal in HBeAg-negative CHB Patients with Low Level HBsAg PegIFN alfa-2b, PegIFN alfa-2b and NUC - Chronic Hepatitis B | Phase 4 | Not yet recruiting | Huashan Hospital | 360 | 2025-04-01 | 2025-03-28 |
| TAF in Early/Middle Pregnancy With CHB TAF, TDF - Hepatitis B Infection, Pregnant Women | Phase 4 | Enrolling by invitation | The Third Affiliated Hospital of Guangzhou Medical University | 816 | 2025-03-31 | 2026-06-25 |
| TAF vs TDF During the Pregancy TAF - Hepatitis B Virus Infection; Pregnant Women | Phase 4 | Enrolling by invitation | The Third Affiliated Hospital of Guangzhou Medical University | 210 | 2024-12-27 | 2026-10-16 |
| Phase IV Study of Concomitant Administration of the sIPV and HepA sIPV (booster dose at 18 months of age), HepA-L, HepA-I - Polio, Hepatitis A | Phase 4 | Not yet recruiting | Institute of Medical Biology, Chinese Academy of Medical Sciences | 2000 | 2024-06-15 | 2024-06-14 |
| ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus Infection Anti-PD-L1 antibody (ASC22), Nucleotide analogs, Peg-IFNα - Chronic Hepatitis b | Phase 4 | Recruiting | The Second Affiliated Hospital of Chongqing Medical University | 120 | 2024-05-21 | 2026-09-01 |
| SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus Dapagliflozin 10mg Tab, Placebo 10mg Tab - Chronic Hepatitis B | Phase 4 | Recruiting | Chinese University of Hong Kong | 412 | 2024-03-26 | 2026-03-18 |
| Efficacy and Durability of Hepatitis A Vaccination in Patients With Advanced Fibrosis and Cirrhosis HAVRIX - Cirrhosis, Hep A | Phase 4 | Unknown | Mahidol University | 50 | 2024-02-29 | 2024-03-19 |
| UHN Inpatient Hepatitis C & B Screening Quality Improvement - Hepatitis C, Hepatitis B | Phase 4 | Unknown | Jordan Feld | 2920 | 2024-02-01 | 2024-02-08 |
Showing 20 of 653. Sign in to see all of them.
Hepatitis B, Chronic (189) · Hepatitis C (184) · Hepatitis B (173) · Hepatitis C, Chronic (144) · Hepatitis A (32) · HIV Infections (26) · Fibrosis (18) · Liver Cirrhosis (18) · Hepatitis (17) · Acquired Immunodeficiency Syndrome (15) · Carcinoma, Hepatocellular (13) · Diphtheria (12) · Tetanus (12) · Haemophilus Infections (10) · Hepatitis E (9)
Digestive System Diseases (651) · Virus Diseases (651) · Infections (649) · Liver Diseases (644) · Hepatitis (636) · Blood-Borne Infections (624) · Communicable Diseases (623) · Pathological Conditions, Signs and Symptoms (371) · Pathologic Processes (369) · Disease Attributes (349) · RNA Virus Infections (348) · Chronic Disease (340) · DNA Virus Infections (334) · Hepadnaviridae Infections (333)
Ribavirin (137) · peginterferon alfa-2a (124) · entecavir (70) · Tenofovir (52) · Sofosbuvir (39) · peginterferon alfa-2b (34) · Lamivudine (33) · sofosbuvir-velpatasvir drug combination (26) · Telbivudine (25) · Hepatitis B Vaccines (24) · adefovir dipivoxil (23) · adefovir (22) · elbasvir-grazoprevir drug combination (20) · tenofovir alafenamide (20) · Hepatitis A Vaccines (18)
GlaxoSmithKline (46) · Hoffmann-La Roche (44) · National Taiwan University Hospital (22) · Third Affiliated Hospital, Sun Yat-Sen University (14) · Merck Sharp & Dohme LLC (13) · Kirby Institute (11) · Massachusetts General Hospital (10) · Nanfang Hospital, Southern Medical University (10) · Kaohsiung Medical University Chung-Ho Memorial Hospital (9) · Bukwang Pharmaceutical (8) · Novartis Pharmaceuticals (8) · Xiamen Innovax Biotech Co., Ltd (7) · Yonsei University (7) · Asan Medical Center (6) · University of California, San Francisco (6)
United States (134) · China (119) · South Korea (60) · Taiwan (52) · Canada (34) · Germany (33) · Spain (26) · Australia (22) · Thailand (21) · Belgium (20) · Brazil (18) · Italy (15) · Egypt (14) · France (12) · United Kingdom (12)
Chen-Hua Liu, MD (9) · Jia-Horng Kao, MD, PhD (6) · Shih-Jer Hsu, MD (6) · Cheng-Chao Liang, MD (5) · Jun Cheng, M.D. (5) · Ming-Lung Yu, MD, PhD (5) · Raymond T Chung, MD (5) · Chih-Lin Lin, MD (4) · Ching-Sheng Hsu, MD (4)
PMID 32710245, PMID 24915612, PMID 28404091, PMID 28404092, PMID 15470215, PMID 19187608, PMID 21182232, PMID 22436845, PMID 23046671, PMID 23518903, PMID 28427875, PMID 29405329, PMID 15014185, PMID 19052126, PMID 19729084, PMID 20009522, PMID 20049753, PMID 21366801, PMID 22045673, PMID 22508412, PMID 22777097, PMID 23732904, PMID 24508042, PMID 24954675, PMID 25348661, PMID 26190091, PMID 26867206, PMID 29696665, PMID 30552056, PMID 30576085, PMID 30689258, PMID 33460002, PMID 34843068, PMID 35599306, PMID 37096802, PMID 39373164, PMID 40390028, PMID 42349783, PMID 10051494, PMID 10613747, PMID 10618544, PMID 11850253, PMID 11855555, PMID 11984144, PMID 12019083, PMID 12375147, PMID 12606735, PMID 12865912, PMID 14697813, PMID 15191208
2005 (4), 2009 (3), 2015 (3), 2004 (2), 2014 (2), 2016 (2), 2019 (1), K23DK082621 (1), R01DA013806 (1), R01DA014502 (1), R01DA016764 (1), R01DA033777 (1), R01DA047952 (1), R21DA016066 (1), R34DA061732 (1)